Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
DS-3201b inhibits EZH1 and EZH2, resulting in decreased H3K27 trimethylation and potentially leading to decreased tumor growth (Blood 2017 130:2073).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DS-3201b||DS-3201|Valemetostat Tosylate||EZH1 inhibitor 3 EZH2 inhibitor 18||DS-3201b inhibits EZH1 and EZH2, resulting in decreased H3K27 trimethylation and potentially leading to decreased tumor growth (Blood 2017 130:2073, PMID: 30658046).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02732275||Phase I||DS-3201b||DS-3201b in Participants With Lymphomas||Recruiting||USA||1|
|NCT04842877||Phase II||DS-3201b||Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma||Recruiting||2|
|NCT04703192||Phase II||DS-3201b||Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)||Recruiting||USA | CAN||4|
|NCT03110354||Phase I||DS-3201b||DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)||Terminated||USA||0|